Multiple Sclerosis Treatment Market: Opportunities for Oral Drugs - New Report by Koncept Analytics

April 6, 2009 - PRLog -- Only about 36% of Multiple Sclerosis (MS) patients are currently treated with MS drugs, this percentage is expected to increase to 56% by 2014 as new oral MS therapies are launched, which shows bright opportunity for oral drugs in multiple sclerosis market. The injectables market is big but leaves certain side effects which bring the possibility for the oral drugs to succeed. It is expected that oral drugs will bring some ease for the patients. In Canada the prevalence rate of MS is the highest with closely followed by United States which is the second most affected region with increasing death rates of MS patients. Also the prevalence rate in Germany, Norway and Hungary is high.  In 2008 the MS treatment market has shown good results despite the slowdown in US and with this success the probability for further growth has increased.

Gender has become a dominant factor in MS during the last decades. The studies have proved that MS prevalence rate is higher in women than man, but the cause of the disease has not been found. MS is the fourth leading cause of disability among American women. Early Age Smoking is also one of the major environmental factors which have increased the chances of MS disease. MS is slowly spreading its reach in the Asian regions. Asia can be a potential market in future.

The report broadly includes the following

1. Introduction: Multiple Sclerosis          

1.1 FDA-Approved Drugs for the Treatment of Multiple Sclerosis  

2. Global Multiple Sclerosis Market          

2.1 Market Size        
Market Value
Prevalence Rate
Mortality Statistics

2.2 Multiple Sclerosis Injectable: Market Share    
Injectables Market Value
Market Share

3. US Multiple Sclerosis Market    
Market Overview
Prevalence Rate

3.1 U.S. Injectables Market  

4. Industry Trends  

5. Opportunities      

6. Competitive Landscape

7. Company Profiles            

7.1 Teva Pharmaceutical Industries
7.2 Biogen    
7.3 Elan Corporation  
7.4 Merck Serono S.A.        

8. Market Outlook    

List of Tables

FDA-Approved Drugs for the Treatment of Multiple Sclerosis
Population Suffering from MS and Prevalence Rate by Region
US Multiple Sclerosis Injectables Market by Penetration Rate (2005-10E)
US Multiple Sclerosis Injectables Market Value by Drugs (2005-08E)
Expected Prevalence of CRPS in MS Patients by Age Group (2007)
Oral Drugs in Late-stage Development for MS
Competing Drugs in Development for MS

List of Charts

Mortality Statistics by Multiple sclerosis by Region (2007)
Market Value of Multiple Sclerosis Treatment (2001-08)
Multiple Sclerosis Injectable Market Share (2007)
MS Injectables Market Value by Drugs (2007)
Tysabri MS Market Value & Projection (2007-09E)
Avonex Market Value & Projection (2005-12E)
Multiple Sclerosis Prevalence in United States (2005-14E)
US MS Affected Population by Categories (2006)
Tysabri Market in United States (2006-08)
Avonex Market Value & Projection for US (2005-12E)
Smoking Among High School Students vs. Men (2001-05)
Number of Deaths Attributable to Smoking in China (2005)
Male/female Ratio of MS in WHO Regions and World (2007)
Commonest MS Diagnostic Criteria Used (2007)
Commonest MS diagnostic Criteria Used in WHO Regions (2007)
US MS Therapies Prescription Trends (2006-07)
US Market for MS Treatment (2009-12E)
United States MS Drugs Revenue by Class (2009-12E)
Teva Pharmaceutical Revenue by Business Segments (2007-08)
Biogen Revenue by Geography (2006-08)
Elan Corporation Revenue by Business Segments (2006-08)

For more details, please visit http://www.konceptanalytics.com/reportDetail.aspx?reportI...

To know more about us http://www.konceptanalytics.com

# # #

Koncept Analytics, founded in 2005, works with the clients in developing an understanding of the various industries – segments and sub-segments, companies, competitors and suppliers.